Atopix raises additional development capital to investigate OC459 for … – News-Medical.net


News-Medical.net

Atopix raises additional development capital to investigate OC459 for
News-Medical.net
Atopix Therapeutics Limited ("Atopix"), a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product …

and more »

View full post on asthma – Google News

Atopix reports positive results from Phase IIb asthma study with OC459 compound – News-Medical.net

Atopix reports positive results from Phase IIb asthma study with OC459 compound
News-Medical.net
Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma 

and more »

View full post on asthma – Google News